The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in ...
A startling investigation has revealed a troubling story behind donanemab's approval -- one of questionable data, potential ...
An investigation has uncovered alarming issues including increased mortality rates, absent safety records, dubious efficacy, ...
Patients tolerated synthetic THC (dronabinol) well, without the adverse effects commonly associated with existing Alzheimer's ...
The U.S. Food and Drug Administration ... the agency approved Cobenfy without a “black box” warning on the regulatory label ...
The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...
26 (UPI) --The U.S. Food and Drug Administration has approved a new drug for adults ... that follows a fall may also speed up progress of dementia, a new study shows. Back to top ...
A BMJ investigation found seven of the eight doctors appointed by the US Food & Drug Administration (FDA) to review donanemab ...
Niemann-Pick disease type C (NPC) is a rare genetic disorder that affects the nervous system and other organs, causing ...
A BMJ investigation found seven of the eight doctors appointed by the US Food & Drug Administration (FDA) to review donanemab ...
Last week, a congressional report found that FDA's approval of a similar Alzheimer's drug called Aduhelm — also from Biogen and Eisai — was “rife with irregularities,” including a number ...
The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in ...